Initial anti-tumor activity data from ABILITY’s fifth and sixth dose escalation cohorts in calendar Q3 2023. Commencement of the ABILITY study’s MDNA11 Phase 2 monotherapy arm expected in calendar Q3 2023. Clinical update from the ABILITY study’s MDNA11 Phase 2 monotherapy arm expected in calendar Q4 2023. Commencement of the MDNA11 plus pembrolizumab combination arm of the ABILITY study in calendar Q4 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDNA:
- Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights
- Medicenna Therapeutics to present as NBTS Research Roundtable
- Medicenna Presents at National Brain Tumor Society’s Research Round Table
- Medicenna Therapeutics extends period to exercise certain warrants
- Oppenheimer waiting for further clinical updates on Medicenna Therapeutics